LitAlert ~~ GeneLit.com

Investigating Psychological Impact after Receiving Genetic Risk Results—A Survey of Participants in a Population Genomic Screening Program.
Zayac McCormick CZ, Dilzell Yu K, Johns A, Campbell-Salome G, Hallquist MLG, Sturm AC, Buchanan AH.
J Pers Med. 2022 Nov 22;12(12):1943. doi: 10.3390/jpm12121943.

The Prospective Lynch Syndrome Database: background, design, main results and complete MySQL code.
Møller P.
Hered Cancer Clin Pract. 2022 Nov 21;20(1):37. doi: 10.1186/s13053-022-00243-z.

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J, Li Q, Zhang L, Zhang S, Dai Y.
Biomed Pharmacother. 2022 Nov 18;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub ahead of print.

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
Wu MS, Goldberg H.
Cancer Manag Res. 2022 Nov 15;14:3159-3174. doi: 10.2147/CMAR.S353411.

[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Tanaka Y, Oota R, Takagi Y, Kodama W, Nishimura K, Hamasaki T, Fukino S, Suo K.
Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273. Japanese.

Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.
Astiazaran-Symonds E, Graham C, Kim J, Tucker MA, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Sampson JN, Zhu B, Bruno W, Queirolo P, Fornarini G, Sciallero S, Carter B, Hicks B, Hutchinson A, Jones K, Stewart DR, Chanock SJ, Freedman ND, Landi MT, Höiom V, Puig S, Gruis N, Yang XR, Ghiorzo P, Goldstein AM.
JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145.

Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma.
Dondi F, Albano D, Bellini P, Camoni L, Treglia G, Bertagna F.
Tomography. 2022 Oct 27;8(6):2662-2675. doi: 10.3390/tomography8060222.